Announcement on Convening the Q3 2025 Performance Briefing
Filed with SSE · · 3 pages · Chinese
BrightGene Bio-Medical Technology Co. Ltd. on 6ix
Earlier from BrightGene Bio-Medical Technology
- Announcement on Waiver of the Preemptive Right for Capital Increase and Stock Expansion of Joint-stock Company and Related Party Transactions
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BGM1812 Injection
- Announcement on Initially Repurchasing the Company's Shares through Call Auction
- Announcement on Voluntary Disclosure of Prospective Winning in the National Centralized Drug Procurement
- Announcement on Receipt of SSE’s "Decision to Terminate the Review of the Private Placement Stock Issuance Application by BrightGene Bio-Medical Technology Co., Ltd."
Later from BrightGene Bio-Medical Technology
- Announcement on Progress in Repurchasing Shares
- Announcement on Implementation Result of Shares Repurchase and Share Changes
- Announcement on Interest Payment for "BrightGene Convertible Bonds" in 2025
- Announcement on Postponing Investment Projects Financed by Raised Funds
- Announcement on Not Redeeming ""BrightGene Convertible Bonds"" in Advance
Follow BrightGene Bio-Medical Technology into a list and get an email when it puts out news.
Follow BrightGene Bio-Medical Technology